MIL •
Healthcare •
Biotechnology •
Quote as of 07/28/2026 15:42
Company Profile
IndustryBiotechnology
SectorHealthcare
ExchangeMIL
Market Capitalization9,019.68 mln
Float89.94 mln
Earnings Date07/31/2026
EPS
0.31
Overpriced
P / E
255
Bubble territory
Piotroski F-Score
4
/ 9
Borderline
Beneish M-Score
-3.3
Reliable
Relative Strength
84
/ 100
Strongly outperforming
Debt / Equity
0.01
Debt-free
Business Description
Corcept Therapeutics is a US-based pharmaceutical company focused on developing drugs that target the effects of cortisol, a hormone that can cause serious harm when the body produces too much of it. Its main product, Korlym, is an approved oral treatment for adults with Cushing's syndrome whose excess cortisol has led to blood sugar problems and who cannot be treated through surgery. The company is also advancing a pipeline of next-generation cortisol-blocking compounds being studied across a range of conditions, including liver disease and ALS. Founded in 1998, Corcept is headquartered in Redwood City, California.
